Precision Medicine in Reproductive Health

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Sex, Gender and Hormone Based Medicine".

Deadline for manuscript submissions: closed (30 August 2023) | Viewed by 10599

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Urology, Peking University First Hospital, Beijing, China
2. Institute of Urology, Peking University, Beijing, China
3. Andrology Center, Peking University First Hospital, Beijing, China
Interests: andrology; reproductive medicine; male infertility; sexual dysfunction
1. Department of Urology, Peking University Third Hospital, Beijing, China
2. Department of Andrology, Peking University Third Hospital, Beijing, China
3. Department of Reproductive Medicine Center, Peking University Third Hospital, Beijing, China
Interests: male infertility; azoospermia; genetic mutation; targeted drug delivery

Special Issue Information

Dear Colleagues,

With increased environmental pollution and delayed reproductive age, reproductive health, especially infertility, has become a major public health issue. Infertility affects about 10–15% of couples of reproductive age, and these individuals experience enormous physical and psychological stress as well as economic burden. In recent decades, with the development of in vitro fertilization, micro-testicular extraction sperm extraction, and targeted drug delivery, many couples suffering from infertility have been able to have their own children. However, there are still many infertility patients, especially with premature ovarian failure, azoospermia, etc., who cannot obtain biological offspring.

In recent years, precision molecular biology technologies such as gene therapy, targeted drugs, and in vitro differentiation systems have developed rapidly, which can remodel the meiotic process in vitro and produce healthy offspring in animal models. A variety of non-invasive detection and fertility assessment models also provide accurate screening methods and have been applied to individuals with infertility. This Special Issue of the Journal of Personalized Medicine aims to highlight some of the recent progresses focused on precision medicine in the diagnosis, prevention, and treatment of patients with infertility.

Prof. Dr. Hui Jiang
Dr. Zhe Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • reproductive medicine
  • precision medicine
  • infertility
  • assisted reproduction
  • targeted drug delivery
  • gene therapy
  • molecular diagnosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 2288 KiB  
Article
Spatiotemporal Trends and Age–Period–Cohort Analysis for the Burden of Endometriosis-Related Infertility: An Analysis of the Global Burden of Disease Study 2019
by Jingchun Liu, Wuyue Han, Haoyu Wang, Zhi Wang, Bingshu Li and Li Hong
J. Pers. Med. 2023, 13(9), 1284; https://doi.org/10.3390/jpm13091284 - 22 Aug 2023
Cited by 2 | Viewed by 1875
Abstract
Background: Endometriosis is a common nonfatal gynecological disease, and infertility is one of its main dangers. Endometriosis-related infertility causes serious damage to women’s health and places a burden on women of reproductive age. The aim of this study was to describe the current [...] Read more.
Background: Endometriosis is a common nonfatal gynecological disease, and infertility is one of its main dangers. Endometriosis-related infertility causes serious damage to women’s health and places a burden on women of reproductive age. The aim of this study was to describe the current burden of endometriosis-associated infertility and to analyze its spatiotemporal trends. Methods: Age-standardized prevalence rate (ASPR) data from 1990 to 2019 for Endometriosis-related primary infertility (ERPI) and secondary infertility (ERSI) were obtained from the Global Burden of Disease Study (GBD) 2019. These data spanning three decades cover the global, sociodemographic index (SDI) regions, GBD regions, and 204 countries and territories. Spatiotemporal trends were analyzed by calculating the estimated annual percentage change (EAPC) and using a time–period–cohort model. Results: Globally, the ASPR of ERPI and ERSI showed a weak downward trend from 1990 to 2019, with EAPCs of −1.25 (95% CI: −1.39 to −1.11) and −0.6 (95% CI: −0.67 to −0.53), respectively. The spatiotemporal trends in ERPI and ERSI varied substantially between regions and age groups. When endometriosis-related infertility burden was linked to SDI values, a strong negative correlation was observed between the ASPR of ERSI and its EAPC and SDI values. When modeling with age–period–cohort, ERPI burden was found to be highest at ages 20–25 years, while ERSI burden was persistently higher at ages 20–45 years. Using 2000–2004 as the reference period, both ERPI and ERSI burden decreased with each year among women. Significant variability in burden between regions was found for the birth cohort factor. Conclusions: The global burden of endometriosis-related infertility declined minimally from 1990 to 2019. However, this burden varied considerably across regions, age groups, periods, and birth cohorts. The results of this study reflect spatiotemporal trends in the burden of endometriosis-related infertility over the study period and may be used to help improve health management, develop timely and effective prevention and control strategies, and provide epidemiologic theoretical evidence for reducing the burden for endometriosis-related infertility. Full article
(This article belongs to the Special Issue Precision Medicine in Reproductive Health)
Show Figures

Figure 1

Review

Jump to: Research

19 pages, 691 KiB  
Review
Microbial Dysbiosis and Male Infertility: Understanding the Impact and Exploring Therapeutic Interventions
by Aris Kaltsas, Athanasios Zachariou, Eleftheria Markou, Fotios Dimitriadis, Nikolaos Sofikitis and Spyridon Pournaras
J. Pers. Med. 2023, 13(10), 1491; https://doi.org/10.3390/jpm13101491 - 13 Oct 2023
Cited by 6 | Viewed by 2429
Abstract
The human microbiota in the genital tract is pivotal for maintaining fertility, but its disruption can lead to male infertility. This study examines the relationship between microbial dysbiosis and male infertility, underscoring the promise of precision medicine in this field. Through a comprehensive [...] Read more.
The human microbiota in the genital tract is pivotal for maintaining fertility, but its disruption can lead to male infertility. This study examines the relationship between microbial dysbiosis and male infertility, underscoring the promise of precision medicine in this field. Through a comprehensive review, this research indicates microbial signatures associated with male infertility, such as altered bacterial diversity, the dominance of pathogenic species, and imbalances in the genital microbiome. Key mechanisms linking microbial dysbiosis to infertility include inflammation, oxidative stress, and sperm structural deterioration. Emerging strategies like targeted antimicrobial therapies, probiotics, prebiotics, and fecal microbiota transplantation have shown potential in adjusting the genital microbiota to enhance male fertility. Notably, the application of precision medicine, which customizes treatments based on individual microbial profiles and specific causes of infertility, emerges as a promising approach to enhance treatment outcomes. Ultimately, microbial dysbiosis is intricately linked to male infertility, and embracing personalized treatment strategies rooted in precision medicine principles could be the way forward in addressing infertility associated with microbial factors. Full article
(This article belongs to the Special Issue Precision Medicine in Reproductive Health)
Show Figures

Figure 1

20 pages, 890 KiB  
Review
Review of Endometrial Receptivity Array: A Personalized Approach to Embryo Transfer and Its Clinical Applications
by Sarah C. Rubin, Mawerdi Abdulkadir, Joshua Lewis, Aleksandr Harutyunyan, Rahim Hirani and Cara L. Grimes
J. Pers. Med. 2023, 13(5), 749; https://doi.org/10.3390/jpm13050749 - 27 Apr 2023
Cited by 11 | Viewed by 5587
Abstract
Successful outcomes of in vitro fertilization (IVF) rely on both the formation of a chromosomally normal embryo and its implantation in a receptive endometrium. Pre-implantation genetic testing for aneuploidy (PGT-A) has been widely accepted as a tool to assess the viability of an [...] Read more.
Successful outcomes of in vitro fertilization (IVF) rely on both the formation of a chromosomally normal embryo and its implantation in a receptive endometrium. Pre-implantation genetic testing for aneuploidy (PGT-A) has been widely accepted as a tool to assess the viability of an embryo. In 2011, the endometrial receptivity array (ERA) was first published as a tool to determine when the endometrium is most receptive to an embryo, commonly referred to as the “window of implantation” (WOI). The ERA uses molecular arrays to assess proliferation and differentiation in the endometrium and screens for inflammatory markers. Unlike PGT-A, there has been dissent within the field concerning the efficacy of the ERA. Many studies that contest the success of the ERA found that it did not improve pregnancy outcomes in patients with an already-good prognosis. Alternatively, studies that utilized the ERA in patients with repeated implantation failure (RIF) and transfer of known euploid embryos demonstrated improved outcomes. This review aims to describe the ERA as a novel technique, review the various settings that the ERA may be used in, such as natural frozen embryo transfer (nFET) and hormone replacement therapy frozen embryo transfer (HRT-FET), and provide a summary of the recent clinical data for embryo transfers in patients with RIF utilizing the ERA. Full article
(This article belongs to the Special Issue Precision Medicine in Reproductive Health)
Show Figures

Figure 1

Back to TopTop